ABSTRACT: β-blockers improve the prognosis of patients with cardiac failure due to left ventricular systolic dysfunction. The aim of this study was to assess the efficacy of β-blockers in patients with dysfunctional systemic right ventricle.
Fourteen patients with systemic right ventricle following a Mustard or a Senning operation for the transposition of the great arteries, or congenitally corrected transposition were included in the study. All had a decreased systemic right ventricular ejection fraction despite having standard cardiac failure therapy. Quality of life, New York Heart Association class, aerobic capacity, and systemic right ventricular function were assessed before treatment with β-blockers and at the end of the follow-up period, mean of 12.8 months with a range from 3 to 36 months.
Change in New York Heart Association class was significant (p = 0.016). Quality of life improved significantly throughout the study from a median grade 2 with a range from 1 to 3 to a median grade 1 with a range from 1 to 2 (p = 0.008). Systemic right ventricular ejection fraction assessed by radionuclide ventriculography improved significantly from a median of 41% (range: 29-53%) to 49% (range: 29-62%; p = 0.031). However, the change in thee ejection fraction assessed by magnetic resonance imaging was not significant from a median of 29% (range: 12-47%) to 32% (range: 22-63%; p = 0.063).
In patients with cardiac failure due to systemic right ventricular dysfunction, β-blockers improve New York Heart Association class, quality of life, and systemic right ventricular ejection fraction assessed by radionuclide ventriculography.
Cardiology in the Young 12/2010; 20(6):615-9. · 0.76 Impact Factor
ABSTRACT: Thrombus aspiration (TA) has been associated with high rates of thrombotic material retrieval, which results in improved myocardial reperfusion. In addition, a recent study has shown that systematic TA for treatment of ST-segment elevation myocardial infarction (STEMI) related to de novo lesions improves patient outcomes.
Evaluation of a single-centre experience of TA before percutaneous coronary intervention (PCI) for stent thrombosis (ST) treatment.
Between 2004 and 2006, we indexed 24 patients presenting with definite ST. All patients underwent TA (Export Medtronic 6F catheter) followed by PCI for ST treatment. Baseline clinical and angiographic characteristics, and complications related to the TA device were indexed.
The median time of ST occurrence was 7 days. All patients except one presented with STEMI. Bare-metal and drug-eluting ST represented 70.8% and 29.2% of cases, respectively. Mean stent length was 18.8 + or - 5.6mm; mean stent diameter was 2.8 + or - 0.4mm; mean number of implanted stents was 1.58 + or - 0.7. There was no failure to cross the catheter and no TA device-related complications were reported. The numbers of patients with initial thrombolysis in myocardial infarction (TIMI) flow grades 0, 1 and 2 were 15 (62.5%), 3 (12.5%) and 6 (25.0%), respectively. No patient had TIMI flow grade 3 before TA. After TA, 16 (66.7%) patients had TIMI flow grade 3; final procedural success was obtained in 23 (95.8%) patients. The 1-year death rate was 12.5%.
In our experience, TA before PCI for ST treatment shows promising results, providing high rates of immediate reperfusion and final angiographic success, and low death rates, compared with the literature.
Archives of cardiovascular diseases 01/2010; 103(1):33-8. · 0.66 Impact Factor
ABSTRACT: Bioprosthetic valve thrombosis is considered extremely unlikely, thus usually allowing patients to avoid long-term anticoagulation. The authors report the case of a patient with late bioprosthetic mitral valve thrombosis associated with a history of postoperative heparin-induced thrombocytopenia. The patient successfully underwent mitral valve replacement.
Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography 08/2009; 22(11):1310.e5-6. · 2.98 Impact Factor
ABSTRACT: Many studies have reported that low final thrombolysis in myocardial infarction (TIMI) flow and/or myocardial blush grade (MBG) are independent predictors of mortality in patients with ST-elevation myocardial infarction (STEMI). In addition, distal coronary embolization is a major pitfall of conventional percutaneous coronary intervention (PCI) in such a context.
This study aimed to assess the impact of thrombus aspiration (TA) use before primary PCI on final myocardial reperfusion in patients presenting with STEMI.
From January to December 2006, 100 patients presenting with STEMI in our catheterization laboratory were considered for the present study. During this time period, 50 patients underwent TA before primary PCI for treatment of STEMI and were then matched 1:1 to 50 controls who underwent conventional primary PCI for treatment of STEMI without TA. Patients of the control group were chosen after matching on age+/-3 years, sex, history of diabetes, and distribution of the infarct related coronary artery during the same period.
Baseline clinical characteristics, initial TIMI flow and initial MBG of both groups were similar. There was a trend for a better final TIMI flow in the group with TA and the final MBG was significantly improved in the group with TA compared to the group without TA: final MBG of two or three in 70% versus 30% of the cases (P=.001). In addition, direct stenting was significantly more often used in the TA group (92% versus 64%, P=.001). There were four patients with evident distal embolizations in the group without TA and none in the group with TA.
TA use before primary PCI for STEMI treatment resulted in improved final myocardial reperfusion. Of importance, TA use may have led to a better choice of the stent size and more frequent direct stenting. This benefit may directly improve patient outcomes.
Cardiovascular revascularization medicine: including molecular interventions 11(3):149-54.